PainReform ( (PRFX) ) has provided an update. PainReform announced that its Phase 3 clinical trial for PRF-110 did not meet ...

SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Phase 3 FLASH2 Trial of HyBryte in CTCL is Underway On December 16, ...

Agreement Reached on Primary Endpoint and Phase 3 Trial DesignOral APX3330 is a Late-Stage Clinical Asset Available for PartneringFARMINGTON ...

Regeneron Pharmaceuticals (REGN) announced the primary endpoint was met in the Phase 3 QUASAR trial investigating EYLEA HD or ...

THRIVE-2 met all primary and secondary endpoints at the 15-week primary analysis timepoint after 5 infusions of veligrotug.

The first patient was enrolled in a phase 3 trial for patients with non-metastatic uveal melanoma to either receive Kimmtrak ...

PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established ...

Both trials recruited patients with psoriatic arthritis who had not previously received biologic disease-modifying ...

Neurosense is finalizing the protocol of a Phase 3 study of PrimeC for ALS, and plans to submit the protocol for FDA approval ...

California-based Apollomics had been testing uproleselan as an adjunct to chemotherapy in relapsed and refractory acute ...

Earlier this month, the company announced positive results for tavapadon, which met both primary and secondary endpoints in a ...

Soligenix opens enrollment for the Phase 3 FLASH2 study of HyBryte in early-stage CTCL, aiming to confirm extended treatment ...